Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Submitted by
admin
on June 2, 2013 - 11:41am
Source:
Yahoo/BusinessWire
News Tags:
Exelixis
Cometriq
thyroid cancer
medullary thyroid cancer
Headline:
Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Do Not Allow Advertisers to Use My Personal information
